Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Arslan, U.; Turker, I.; Aksoy, S.; Oksuzoglu, B.; Helvaci, K.; Ozdemir, N.; Uyeturk, U.; Sonmez, O.; Budakoglu, B.; Zengin, N.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Atıf İçin Kopyala

Arslan U. Y., Turker I., Aksoy S., Oksuzoglu B., Helvaci K., Ozdemir N. Y., ...Daha Fazla

JOURNAL OF BUON, cilt.18, sa.3, ss.585-593, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 3
Basım Tarihi: 2013
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.585-593
Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: The duration of anti-HER2 blockage therapy in metastatic breast cancer patients is still unclear. We aimed to evaluate the effect of the anti-HER2 blockage therapy duration and other factors on survival in HER2 positive metastatic breast carcinoma (MBC) patients.